GWP.L Regulatory News (GWP)

28 Feb 2007 07:00

GW Pharmaceuticals PLC28 February 2007 Phase III Sativex(R) Data Published in Leading Neurology Journal Data demonstrate that Sativex provides relief of spasticity for patients with Multiple Sclerosis Porton Down, UK, 28th February 2007 - A leading neurology journal, The EuropeanJournal of Neurology, today reports a study showing that Sativex significantlyreduces intractable spasticity (spasms and stiffness) in people with MultipleSclerosis (MS). The publication of these data follows the previous announcement of preliminaryresults of this 189 patient study, which forms part of the regulatory filing forSativex for MS spasticity submitted in September 2006 in selected Europeancountries. In the randomised, double-blind trial, led by Professor Christine Collin fromthe Royal Berkshire and Battle NHS Trust, Reading, UK, Sativex demonstratedsignificant superiority to placebo in reducing spasticity (p